{
    "id": 28168,
    "cites": 29,
    "cited_by": 0,
    "reference": [
        "Acemoglu, Daron and Joshua Lim. (2004) \u00c3\u00a2\u00c2\u0080\u00c2\u009cMarket Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Quarterly Journal of Economics 119(3): 1049\u00c3\u00a2\u00c2\u0080\u00c2\u00931090.",
        "Athey, Susan, Michael Kremer, Christopher M. Snyder, and Alex Tabarrok. (2020) \u00c3\u00a2\u00c2\u0080\u00c2\u009cIn the Race for a Coronavirus Vaccine, We Must Go Big. Really, Really Big,\u00c3\u00a2\u00c2\u0080\u00c2\u009d New York Times May 4.",
        "Berndt, Ernst, Rachel Glennerster, Michael Kremer, Jean Lee, Ruth Levine, Georg Weizs\u00c3\u0083\u00c2\u00a4cker, and Heidi Williams. (2007) \u00c3\u00a2\u00c2\u0080\u00c2\u009cAdvance Market Commitments for Vaccines Against Neglected Diseases: Estimating Costs and Effectiveness,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Health Economics 16(5): 491\u00c3\u00a2\u00c2\u0080\u00c2\u0093511.",
        "Berndt, Ernst R. and John A. Hurvitz. (2005) \u00c3\u00a2\u00c2\u0080\u00c2\u009cVaccine Advance-Purchase Agreements For LowIncome Countries: Practical Issues\u00c3\u00a2\u00c2\u0080\u00c2\u009d Health Affairs 24(3): 653\u00c3\u00a2\u00c2\u0080\u00c2\u0093665.",
        "Cernuschi, Tania, Eliane Furrer, Nina Schwalbe, Andrew Jones, Ernst R. Berndt, and Susan McAdams. (2011) \u00c3\u00a2\u00c2\u0080\u00c2\u009cAdvance Market Commitment for Pneumococcal Vaccines: Putting Theory into Practice,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Bulletin of the World Health Organization 89: 913\u00c3\u00a2\u00c2\u0080\u00c2\u0093918.",
        "Chalkidou, Kalipso, Hannah Kettler, Ganesh Ramakrishnan, Rachel Silverman, and Adrian Towse. (2020a) \u00c3\u00a2\u00c2\u0080\u00c2\u009cLeave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Center for Global Development note, Washington DC.",
        "Chalkidou, Kalipso, Adrian Towse, Rachel Silverman, Martina Garau, and Ganesh Ramakrishnan. (2020b) \u00c3\u00a2\u00c2\u0080\u00c2\u009cMarket-Driven, Value-Based, Advance Commitment (MVAC): Accelerating the Development of a Pathbreaking Universal Drug Regimen to End TB,\u00c3\u00a2\u00c2\u0080\u00c2\u009d BMJ Global Health 5 (e002061): 1\u00c3\u00a2\u00c2\u0080\u00c2\u00936.",
        "Department for International Development. (2009) \u00c3\u00a2\u00c2\u0080\u00c2\u009cAdvance Market Commitments for LowCarbon Development: An Economic Assessment (Final Report),\u00c3\u00a2\u00c2\u0080\u00c2\u009d London.",
        "GAVI. (2020) \u00c3\u00a2\u00c2\u0080\u00c2\u009cCOVAX Explained,\u00c3\u00a2\u00c2\u0080\u00c2\u009d [Internet.] Downloaded November 4, 2020 from https://ww w.gavi.org/vaccineswork/covax-explained.",
        "Kremer, Michael. (1998) \u00c3\u00a2\u00c2\u0080\u00c2\u009cPatent Buyouts: A Mechanism for Encouraging Innovation,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Quarterly Journal of Economics 113(4): 1137\u00c3\u00a2\u00c2\u0080\u00c2\u00931167.",
        "Kremer, Michael. (2000a) \u00c3\u00a2\u00c2\u0080\u00c2\u009cCreating Markets for New Vaccines. Part I: Rationale,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Innovation Policy and the Economy 1: 35\u00c3\u00a2\u00c2\u0080\u00c2\u009372.",
        "Kremer, Michael. (2000b) \u00c3\u00a2\u00c2\u0080\u00c2\u009cCreating Markets for New Vaccines. Part II: Design Issues,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Innovation Policy and the Economy 1: 73\u00c3\u00a2\u00c2\u0080\u00c2\u0093118.",
        "Kremer, Michael and Rachael Glennerster, Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press, 2004.",
        "Kremer, Michael, Jonathan Levin, and Christopher M. Snyder. (2020) \u00c3\u00a2\u00c2\u0080\u00c2\u009cAdvance Market Commitments: Insights from Theory and Experience,\u00c3\u00a2\u00c2\u0080\u00c2\u009d American Economic Association Papers and Proceedings 110: 269\u00c3\u00a2\u00c2\u0080\u00c2\u0093273.",
        "Kremer, Michael and Heidi Williams. (2010) \u00c3\u00a2\u00c2\u0080\u00c2\u009cIncentivizing Innovation: Adding to the Tool Kit,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Innovation Policy and the Economy 10: 1\u00c3\u00a2\u00c2\u0080\u00c2\u009317.",
        "Levine, Orin, \u00c3\u00a2\u00c2\u0080\u00c2\u009cGAVI Alliance Investment Case: Accelerating the Introduction of Pneumococcal Vaccine into GAVI-Eligible Countries,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Pneumo-ADIP, October 26, 2006.",
        "Levine, Ruth, Michael Kremer, and Alice Albright. (2005) Making Markets for Vaccines: Ideas to Action. Washington, DC: Center for Global Development.",
        "Light, Donald. (2005) \u00c3\u00a2\u00c2\u0080\u00c2\u009cMaking Practical Markets for Vaccines,\u00c3\u00a2\u00c2\u0080\u00c2\u009d PLoS Medicine 2(10): 934\u00c3\u00a2\u00c2\u0080\u00c2\u0093938.",
        "Ozawa, Sachiko, Andrew Mirelman, Meghan L. Stack, Damian G. Walker, and Orin S. Levine. (2012) \u00c3\u00a2\u00c2\u0080\u00c2\u009cCost-Effectiveness and Economic Benefits of Vaccines in Low- and Middle-Income Countries: A Systematic Review,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Vaccine 31(1): 96\u00c3\u00a2\u00c2\u0080\u00c2\u0093108.",
        "Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. (2006) \u00c3\u00a2\u00c2\u0080\u00c2\u009cDeveloping Drugs for Developing Countries,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Health Affairs 25(2): 313\u00c3\u00a2\u00c2\u0080\u00c2\u0093324.",
        "Scudellari, Megan. (2011) \u00c3\u00a2\u00c2\u0080\u00c2\u009cAre Advance Market Commitments for Drugs a Real Advance?\u00c3\u00a2\u00c2\u0080\u00c2\u009d Nature Medicine 17(2): 139.",
        "Sinha, Anushua, Orin S. Levine, Maria D. Knoll, Tracy A. Lieu. (2007) \u00c3\u00a2\u00c2\u0080\u00c2\u009cCost Effectiveness of Pneumococcal Conjugate Vaccination in the Prevention of Childhood Mortality: An International Economic Analysis,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Lancet 369(9559): 389\u00c3\u00a2\u00c2\u0080\u00c2\u0093396.",
        "Sonderholm, Jorn. (2011) \u00c3\u00a2\u00c2\u0080\u00c2\u009cA Theoretical Flaw in the Advance Market Commitment Idea,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Journal of Medical Ethics 36: 339\u00c3\u00a2\u00c2\u0080\u00c2\u0093343.",
        "Snyder, Christopher M., Kendall Hoyt, Dimitrios Gouglas, Thomas Johnston, and James Robinson. (2020) \u00c3\u00a2\u00c2\u0080\u00c2\u009cDesigning Pull Funding For A COVID-19 Vaccine,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Health Affairs 39(9): 1633\u00c3\u00a2\u00c2\u0080\u00c2\u00931642.",
        "U.S. Health and Human Services. (2020) \u00c3\u00a2\u00c2\u0080\u00c2\u009cU.S. Government Engages Pfizer to Produce Millions of Doses of COVID-19 Vaccine.\u00c3\u00a2\u00c2\u0080\u00c2\u009d [Internet.] Downloaded November 23, 2020 from https: //www.hhs.gov/about/news/2020/07/22/us-government-engages-pfizer-produce-millionsdoses -covid-19-vaccine.html.",
        "von Braun, Joachim, et al. (2012) \u00c3\u00a2\u00c2\u0080\u00c2\u009cInnovative Financing for Agriculture, Food Security, and Nutrition, \u00c3\u00a2\u00c2\u0080\u00c2\u009d International Expert Report to Leading Group on Innovative Financing to Fund Development, Paris.",
        "Weyl, E. Glen and Jean Tirole. (2012) \u00c3\u00a2\u00c2\u0080\u00c2\u009cMarket Power Screens Willingness-to-Pay,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Quarterly Journal of Economics 127(4): 1971\u00c3\u00a2\u00c2\u0080\u00c2\u00932003.",
        "World Bank and GAVI. (2006) \u00c3\u00a2\u00c2\u0080\u00c2\u009cFramework Document: Pilot AMC for Pneumococcal Vaccines.\u00c3\u00a2\u00c2\u0080\u00c2\u009d Document prepared for second Donor Working Group meeting November 9, 2006. [Internet.",
        "World Health Organization (2007) \u00c3\u00a2\u00c2\u0080\u00c2\u009cPnuemococcal Conjugate Vaccine for Childhood Immunization\u00c3\u00a2\u00c2\u0080\u00c2\u0094 WHO Position Paper,\u00c3\u00a2\u00c2\u0080\u00c2\u009d Weekly Epidemiological Record 82(12): 93\u00c3\u00a2\u00c2\u0080\u00c2\u0093104."
    ]
}